FI952169A - Stabiili valmiste veren koagulaatiohäiriöiden hoitamiseksi - Google Patents

Stabiili valmiste veren koagulaatiohäiriöiden hoitamiseksi Download PDF

Info

Publication number
FI952169A
FI952169A FI952169A FI952169A FI952169A FI 952169 A FI952169 A FI 952169A FI 952169 A FI952169 A FI 952169A FI 952169 A FI952169 A FI 952169A FI 952169 A FI952169 A FI 952169A
Authority
FI
Finland
Prior art keywords
blood
treatment
clotting disorders
stable preparation
clotting
Prior art date
Application number
FI952169A
Other languages
English (en)
Swedish (sv)
Other versions
FI952169A0 (fi
Inventor
Johann Eibl
Hans Peter Schwarz
Juergen Siekmann
Peter Turecek
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of FI952169A0 publication Critical patent/FI952169A0/fi
Publication of FI952169A publication Critical patent/FI952169A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI952169A 1994-05-06 1995-05-05 Stabiili valmiste veren koagulaatiohäiriöiden hoitamiseksi FI952169A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4416166A DE4416166C2 (de) 1994-05-06 1994-05-06 Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen

Publications (2)

Publication Number Publication Date
FI952169A0 FI952169A0 (fi) 1995-05-05
FI952169A true FI952169A (fi) 1995-11-07

Family

ID=6517569

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952169A FI952169A (fi) 1994-05-06 1995-05-05 Stabiili valmiste veren koagulaatiohäiriöiden hoitamiseksi

Country Status (8)

Country Link
US (1) US5698677A (fi)
EP (1) EP0680764A3 (fi)
JP (1) JP3051650B2 (fi)
AT (1) ATA76995A (fi)
CA (1) CA2148746A1 (fi)
DE (1) DE4416166C2 (fi)
FI (1) FI952169A (fi)
NO (1) NO951761L (fi)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017891A (en) * 1994-05-06 2000-01-25 Baxter Aktiengesellschaft Stable preparation for the treatment of blood coagulation disorders
DE4416180C2 (de) * 1994-05-06 1997-08-14 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats
DE4430205A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
DK0796623T3 (da) * 1996-03-20 2005-08-01 Baxter Ag Farmaceutisk præparat til behandling af blodkoagulationslidelser
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AT407484B (de) 1997-11-12 2001-03-26 Bio Prod & Bio Eng Ag Arzneimittel zur förderung der wundheilung
WO1999066939A1 (en) * 1998-06-23 1999-12-29 Marder Victor J Phospholipid vesicle-tissue factor complex preparations and methods of making and using same
US6277337B1 (en) 1998-07-21 2001-08-21 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US6258577B1 (en) 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
US6268120B1 (en) 1999-10-19 2001-07-31 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US6248353B1 (en) 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
US7985588B2 (en) 2000-06-02 2011-07-26 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US7648699B2 (en) 2000-06-02 2010-01-19 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
TW590780B (en) 2000-06-02 2004-06-11 Gambro Inc Additive solutions containing riboflavin
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US6596543B2 (en) 2001-03-22 2003-07-22 Dade Behring Inc. Use of liposomes of defined composition and size for the preparation of prothrombin time reagents
US7015193B2 (en) * 2001-04-20 2006-03-21 University Of Vermont Compositions and methods to control bleeding
US7125846B2 (en) 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
RS20050051A (en) 2002-07-23 2007-06-04 Bio-Products & Bio Engineering Ag., Pharmaceutical active ingredient preparation and medicaments that contain thrombin or have a thrombin-generating capacity
WO2004011023A1 (de) * 2002-07-23 2004-02-05 Bio-Products & Bio-Engineering Aktiengesellschaft Thrombingenerierfähige und thrombinhältige pharmazeutische wirkstoffzubereitungen und arzneimittel
WO2004087198A1 (en) * 2003-04-03 2004-10-14 Canadian Blood Services Use of coagulation proteins to lyse clots
US7671013B2 (en) 2003-04-03 2010-03-02 Canadian Blood Services, Inc. Coagulation proteins, coagulation-anticoagulation protein complexes, derivatives thereof and their uses
HUE031380T2 (en) * 2005-06-27 2017-07-28 Glaxosmithkline Biologicals Sa A method for producing vaccines
DE102006008613A1 (de) 2006-02-24 2007-08-30 Dade Behring Marburg Gmbh Stabilisierte Zubereitungen von Serin-Endopeptidasen, deren Herstellung und Verwendung
JP5160534B2 (ja) * 2006-03-30 2013-03-13 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 低免疫原性および長時間循環性タンパク質−脂質複合体の組成物
EP1939218A1 (en) * 2006-12-29 2008-07-02 Thrombotargets Europe, S.L. Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
GB201122430D0 (en) * 2011-12-23 2012-02-08 Xstalbio Ltd Reconstitution method for high concentration dry protein formulation
CA2929671A1 (en) * 2013-11-04 2015-05-07 The Regents Of The University Of California Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241046A (en) * 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
AT368883B (de) * 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
JPS5770814A (en) * 1980-10-17 1982-05-01 Isamu Horikoshi Oral preparation of blood clotting eighth factor
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
GB2129685B (en) * 1982-11-11 1985-11-13 Nat Biolog Standards Board Anti-haemophilic compositions
US4610880A (en) * 1983-06-27 1986-09-09 Queen's University At Kingston Composition for controlling hemophilia in mammals
US4721618A (en) * 1983-06-27 1988-01-26 Queen's University At Kingston Method for controlling bleeding
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US4937324A (en) * 1987-02-06 1990-06-26 Zymogenetics, Inc. Chromatographic purification of human proteins having anticoagulant and anti-inflammatory activity
WO1990003808A1 (en) * 1988-10-07 1990-04-19 The Liposome Company, Inc. Heat treating liposomes
WO1991002532A2 (en) * 1989-08-14 1991-03-07 Queen's University At Kingston Method for stimulating fibrinolytic effect
DE3942933A1 (de) * 1989-12-23 1991-06-27 Boehringer Mannheim Gmbh Verwendung von alkylphospholipiden als antivirale arzneimittel und neue phospholipid-derivate
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
ES2131504T3 (es) * 1990-02-20 1999-08-01 Baxter Int Trombina humana purificada viricamente segura.
US5418130A (en) * 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
DE4325872C1 (de) * 1993-08-02 1994-08-04 Immuno Ag Virusinaktivierte Faktor Xa-Präparation
CA2168671C (en) * 1993-08-06 2007-04-10 Yechezkel Barenholz A method for high loading of vesicles with biopolymeric substances
DE4416180C2 (de) * 1994-05-06 1997-08-14 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats

Also Published As

Publication number Publication date
JPH07304658A (ja) 1995-11-21
EP0680764A3 (en) 1998-01-28
ATA76995A (de) 2002-04-15
US5698677A (en) 1997-12-16
NO951761L (no) 1995-11-07
JP3051650B2 (ja) 2000-06-12
CA2148746A1 (en) 1995-11-07
FI952169A0 (fi) 1995-05-05
DE4416166A1 (de) 1995-11-09
DE4416166C2 (de) 1997-11-20
EP0680764A2 (en) 1995-11-08
NO951761D0 (no) 1995-05-05

Similar Documents

Publication Publication Date Title
FI952169A (fi) Stabiili valmiste veren koagulaatiohäiriöiden hoitamiseksi
HUP9700603A3 (en) Pharmaceutical preparation for the treatment of blood coagulation disorders
DE60023873D1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
NO910828L (no) Preparat for behandling av erektil funksjonssvikt.
DK0730864T3 (da) Lægemiddel til behandling af inflammatoriske hjertesygdomme
DE59711321D1 (de) Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen
NO952573D0 (no) Blandinger for behandling av diabetiske komplikasjoner
DE69903543T2 (de) Formulierungen zur behandlung von magen-speiseröhren reflux
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
NO20005884D0 (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
NO963568D0 (no) Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse
NO990722D0 (no) FremgangsmÕte for behandling av hjertesvikt
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
ITTO940748A0 (it) Condotto protesico particolarmente per il trattamento di patologie cardiovascolari.
DE69807466T2 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
NO973081D0 (no) Fremgangmåte for behandling av kroniske progressive vaskulære sykdommer
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
NO991164D0 (no) Farmas°ytisk preparat for behandling av virussykdommer
DE69738320D1 (de) Verwendung von pyrolidin-derivaten zur herstellung von arzneimitteln zur behandlung von drogenmissbrauch
NO951762D0 (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff
NO952411D0 (no) Midler for behandling av metaboliske bensykdommer
DE69813354D1 (de) Mittel zur Behandlung von Herzkrankheiten
FI972694A0 (fi) Uusi menetelmä sameridiinin valmistamiseksi
ATE261965T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien

Legal Events

Date Code Title Description
FD Application lapsed